Mercer Global Advisors
SRNE

Mercer Global Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Mercer Global Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,717
Closed -$60K – 1283
2019
Q4 		$60K Buy
17,717
+738
+4% +$1.76K ﹤0.01% 1140
2019
Q3 		$36K Sell
16,979
-1,325
-7% -$3.09K ﹤0.01% 1109
2019
Q2 		$49K Buy
18,304
+2,250
+14% +$8.1K ﹤0.01% 1123
2019
Q1 		$76K Buy
+16,054
New +$42.1K ﹤0.01% 1033

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mercer Global Advisors's SRNE Position: Q1 2020 in Review

Mercer Global Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2020, closing a stake of 17,717 shares — an estimated $60K sold.

Mercer Global Advisors first reported a position in SRNE in Q1 2019 and held it in 4 quarters. The position peaked at $76K in Q1 2019. 92 funds tracked by Wall St. Rank hold SRNE as of Q1 2020.

  • Mercer Global Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Mercer Global Advisors sold 17,717 Sorrento Therapeutics, Inc. shares in Q1 2020, an estimated $60K.
  • Mercer Global Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2019 and held it in 4 quarters.
  • Mercer Global Advisors's Sorrento Therapeutics, Inc. position peaked at $76K in Q1 2019.
  • 92 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2020.

Based on Mercer Global Advisors's 13F filing for Q1 2020, filed 18 May 2020.